JPMorgan analyst Anupam Rama lowered the firm’s price target on Sage Therapeutics (SAGE) to $8.50 from $11 and keeps a Neutral rating on the shares. The firm cites the acquisition deal price by Supernus Pharmaceuticals for the target cut.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Avidity, BridgeBio, Coty, SAGE, Alkermes: Trending by Analysts
- Sage Therapeutics price target raised to $9 from $7 at Baird
- H.C. Wainwright sees potential competition for Sage from Biogen
- Sage Therapeutics price target raised to $9 from $8 at Truist
- Hold Rating on SAGE Therapeutics Amid Uncertainty and Acquisition Developments